https://www.intechopen.com/online-first/82798
Abstract
Clinical, biological, and radiological evidence are currently needed to diagnose MS, but lack of preclinical biomarkers hinders the earliest possible diagnosis and treatment.
Conventional biomarkers target immunity, blood-brain barrier disruption, demyelination, and neuronal and axonal damage, as well as mitochondrial activity. An increase of specific brain metabolites with 30–40% is registered before detection of MRI lesions in MS. Potential lipid biomarkers are fatty acids, phospholipids, and oxysterols. The role of proteoforms in the pathogenesis of MS was confirmed. Serum neurofilament light chains (sNfL) are currently being studied as a readily available biomarker for prognosis and response to treatment in MS.
The sNfL levels reflect ongoing neuroaxonal damage caused by inflammation, and the sNfL levels predict disease activity over the next few years. The retinal nerve fiber layer (RNFL) thinning is reliable as a biomarker of disability worsening. The neutrophil-to-lymphocyte ratio and CRP are also MS biomarkers.
The development of rationally targeted therapeutic agents that allow preventive treatment to stop the disease is also delayed without definite biomarkers.
biomarkers in MS as of 2022
-
- Similar Topics
- Replies
- Views
- Last post
-
- 2 Replies
- 1015 Views
-
Last post by jimmylegs
-
- 0 Replies
- 1036 Views
-
Last post by frodo
-
- 0 Replies
- 1608 Views
-
Last post by frodo
-
- 0 Replies
- 1216 Views
-
Last post by frodo
-
- 0 Replies
- 2505 Views
-
Last post by NHE
-
- 0 Replies
- 1740 Views
-
Last post by frodo
-
- 0 Replies
- 1673 Views
-
Last post by frodo
-
- 0 Replies
- 1210 Views
-
Last post by frodo
-
- 0 Replies
- 1458 Views
-
Last post by frodo